Advertisement
Advertisement
KYMR
Kymera Therapeutics, Inc. Common Stock
114.96
USDSponsored
-2.04
-1.74%
Sep 11, 15:59 UTC -4
Closed
Pre-Market
113.48
-1.48
-1.29%
KYMR Earnings Reports
Positive Surprise Ratio
KYMR beat 8 of 24 last estimates.
33%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$3.17M
/-$1.25
Implied change from Q2 26 (Revenue/ EPS)
-95.13%
/+101.61%
Implied change from Q3 25 (Revenue/ EPS)
+14.52%
/+32.98%
Kymera Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, KYMR reported earnings of -0.62 USD per share (EPS) for Q2 26, beating the estimate of -0.72 USD, resulting in a 14.75% surprise. Revenue reached 65.00 million, compared to an expected 31.79 million, with a 104.48% difference. The market reacted with a +1.04% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 13 analysts forecast an EPS of -1.25 USD, with revenue projected to reach 3.17 million USD, implying an increase of 101.61% EPS, and decrease of -95.13% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.62, beating estimates by 14.75%, and revenue of $65.00M, 104.48% above expectations.
How did the market react to Kymera Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 1.04%, changed from $104.39 before the earnings release to $105.48 the day after.
When is Kymera Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?
Based on 13
analysts, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$1.25 and revenue of $3.17M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.